Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Sees Large Increase in Short Interest

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 34,593 shares, a growth of 411.8% from the August 15th total of 6,759 shares. Based on an average daily trading volume, of 31,550 shares, the short-interest ratio is currently 1.1 days. Approximately 2.4% of the company’s stock are short sold.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

A number of large investors have recently bought and sold shares of GNOM. Creative Financial Designs Inc. ADV grew its holdings in shares of Global X Genomics & Biotechnology ETF by 4.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock worth $551,000 after purchasing an additional 481 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Global X Genomics & Biotechnology ETF by 30.9% during the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock valued at $164,000 after purchasing an additional 4,615 shares during the period. Wealth Management Partners LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF in the first quarter valued at $244,000. Jane Street Group LLC raised its stake in shares of Global X Genomics & Biotechnology ETF by 7.7% in the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after purchasing an additional 10,308 shares in the last quarter. Finally, Sei Investments Co. raised its stake in shares of Global X Genomics & Biotechnology ETF by 110.4% in the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after purchasing an additional 12,105 shares in the last quarter. 56.95% of the stock is currently owned by institutional investors.

Global X Genomics & Biotechnology ETF Trading Up 0.4%

NASDAQ GNOM traded up $0.25 during trading on Friday, reaching $62.22. The company’s stock had a trading volume of 17,643 shares, compared to its average volume of 18,027. The stock has a market capitalization of $90.84 million, a PE ratio of -26.59 and a beta of 1.19. The business has a 50-day moving average price of $59.49 and a 200-day moving average price of $51.50. Global X Genomics & Biotechnology ETF has a 1-year low of $36.13 and a 1-year high of $68.00.

Global X Genomics & Biotechnology ETF Dividend Announcement

The firm also recently declared a semiannual dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 29th were issued a dividend of $0.0579 per share. The ex-dividend date was Monday, June 29th. This represents a dividend yield of 20.0%. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is currently -27.35%.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.